Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
1.200
-0.020 (-1.64%)
Apr 1, 2025, 4:00 PM EDT - Market closed

Climb Bio Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-73.9-35.12-45.24-47.48-20.67
Upgrade
Asset Writedown & Restructuring Costs
51.660.18--9.16
Upgrade
Loss (Gain) From Sale of Investments
-0.76-2.33-0.180.37-
Upgrade
Stock-Based Compensation
5.5612.816.993.740.71
Upgrade
Other Operating Activities
0.180.10.8511.47-0.36
Upgrade
Change in Accounts Payable
-1.14-0.69-0.650.32-0.02
Upgrade
Change in Other Net Operating Assets
2.844.450.86-4.49-2.91
Upgrade
Operating Cash Flow
-15.56-20.6-37.37-36.07-14.1
Upgrade
Cash Acquisitions
-4.65---8.28
Upgrade
Sale (Purchase) of Intangibles
-----0.2
Upgrade
Investment in Securities
-111.4568.9834.44-114.97-
Upgrade
Investing Cash Flow
-121.0968.9834.44-114.978.08
Upgrade
Issuance of Common Stock
130.980.84-83.29-
Upgrade
Other Financing Activities
-0.25----
Upgrade
Financing Cash Flow
130.730.84-177.234.93
Upgrade
Foreign Exchange Rate Adjustments
0.040.3-0.410.250.36
Upgrade
Net Cash Flow
-5.8849.53-3.3426.44-0.74
Upgrade
Levered Free Cash Flow
-9.543.46-20.51-25.3-6.57
Upgrade
Unlevered Free Cash Flow
-9.543.46-20.51-25.3-6.57
Upgrade
Change in Net Working Capital
-1.78-4.07-0.716.74-0.28
Upgrade
Updated Mar 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q